Our company’s Foundation committed $30 million over eight years (2005–2012), and an additional $6 million over three years (2014–2016), to address the growing burden of HIV/AIDS in China and help support the National HIV/AIDS Prevention and Control Action Plan.
The China-MSD HIV/AIDS Partnership (C-MAP) officially launched in 2007 in Sichuan Province as an innovative public-private partnership to advance improvements in HIV awareness and prevention, counseling and testing uptake, and treatment coverage. C-MAP was the first large-scale partnership between the Chinese government and a multinational company to focus on HIV/AIDS prevention and control.
Since 2007, C-MAP has successfully established an overall HIV prevention and treatment network in Sichuan Province. The partnership also developed an integrated disease management model and achieved significant progress in raising HIV awareness among the general public, improving HIV testing rates, improving the capacity of local health care providers, and expanding antiretroviral treatment (ART) coverage.
In its second phase (2014–2016), C-MAP is working to strengthen integrated HIV treatment capacity and coverage and to promote cooperation between the township and county health systems of Sichuan Province’s Liangshan Prefecture. The program has expanded to new sites in Chongqing Municipality and Fujian Province. The partnership continues its focus on improving HIV/AIDS management and treatment services by strengthening the capacity of health care workers to support effective patient referrals and by promoting quality HIV care through health worker training in effective HIV diagnosis, treatment and disease management.
C-MAP focuses on the following key program objectives:
- Promoting HIV counseling and testing to improve early diagnosis of HIV-positive (HIV+) patients and timely entry into care and treatment
- Improving effective referral of newly diagnosed HIV+ patients to ART services
- Enhancing the capacity and capability of primary health care workers to support effective patient referral and promote high-quality HIV treatment services
- Expanding ART coverage for eligible HIV+ patients
- Increasing patient adherence to antiretroviral treatment
The second phase of C-MAP, launched in 2014, has achieved significant progress in treatment coverage, patient referrals and adherence, and physician training. The performance indicators below reflect aggregate data from across the Sichuan Province, Liangshan Prefecture; Chongqing Municipality; and Fujian Province.
|C-MAP Phase II Metrics|
|Investment by our company's Foundation (in millions)||$3.0||$2.5|
|HIV Testing, and Patient Referrals and Treatment|
|Number of people who have received HIV testing and counseling||236,625||125,405|
|HIV test and detection efficiency ratio (percentage of new HIV+ detection among number of HIV tests)||0.07%||0.11%|
|Percentage and number of successful patient referrals to treatment services1||90.2%|
|Antiretroviral Treatment (ART)|
|Newly diagnosed adults who are receiving ART||3,764||4,528|
|HIV+ adults who are receiving ART||9,200||14,842|
|Newly diagnosed children who are receiving ART||31||40|
|Children with HIV who are receiving ART||81||129|
|Proportion of eligible patients receiving ART||80.9%||79%|
|Proportion of patients who are adherent to ART for 12 months||94.1%||95.3%|
|Rate of viral load suppression (viral load less than 400 copies) among patients who are adherent to ART for 12 months||74.6%||73.4%|
|Health Care Capacity-Building|
|Physicians who received training||1,856||1,928|
|1 Successful referral is defined as those patients who are referred from a testing site to an ART center and remain on treatment for at least one month.|